1932

Abstract

For almost 50 years, ebolaviruses and related filoviruses have been repeatedly reemerging across the vast equatorial belt of the African continent to cause epidemics of highly fatal hemorrhagic fever. The 2013-2015 West African epidemic, by far the most geographically extensive, most fatal, and longest lasting epidemic in Ebola's history, presented an enormous international public health challenge, but it also provided insights into Ebola's pathogenesis and natural history, clinical expression, treatment, prevention, and control. Growing understanding of ebolavirus pathogenetic mechanisms and important new clinical observations of the disease course provide fresh clues about prevention and treatment approaches. Although viral cytopathology and immune-mediated cell damage in ebolavirus disease often result in severe compromise of multiple organs, tissue repair and organ function recovery can be expected if patients receive supportive care with fluids and electrolytes; maintenance of oxygenation and tissue perfusion; and respiratory, renal, and cardiovascular support. Major challenges for managing future Ebola epidemics include establishment of early and aggressive epidemic control and earlier and better patient care and treatment in remote, resource-poor areas where Ebola typically reemerges. In addition, it will be important to further develop Ebola vaccines and to adopt policies for their use in epidemic and pre-epidemic situations.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pathol-052016-100506
2017-01-24
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/pathol/12/1/annurev-pathol-052016-100506.html?itemId=/content/journals/10.1146/annurev-pathol-052016-100506&mimeType=html&fmt=ahah

Literature Cited

  1. 1. WHO (World Health Organ.) Ebola Response Team 2016. After Ebola in West Africa—unpredictable risks, preventable epidemics. N. Engl. J. Med. 375:587–96 [Google Scholar]
  2. 2. WHO (World Health Organ.) 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull. World Health Organ. 56:271–93 [Google Scholar]
  3. McCormick JB, Bauer SP, Elliott LH, Webb PA, Johnson KM. 3.  1983. Biologic differences between strains of Ebola virus from Zaire and Sudan. J. Infect. Dis. 147:264–67 [Google Scholar]
  4. Richman DD, Cleveland PH, McCormick JB, Johnson KM. 4.  1983. Antigenic analysis of strains of Ebola virus: identification of two Ebola virus serotypes. J. Infect. Dis. 147:268–71 [Google Scholar]
  5. Breman JG, Johnson KM, van der Groen G, Robbins CB, Szczeniowski MV. 5.  et al. 1999. A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: ecologic, virologic, and serologic surveys, 1979–1980. Ebola Virus Study Teams.. J. Infect. Dis. 179:Suppl. 1S139–47 [Google Scholar]
  6. Peterson AT, Carroll DS, Mills JN, Johnson KM. 6.  2004. Potential mammalian filovirus reservoirs. Emerg. Infect. Dis. 10:2073–81 [Google Scholar]
  7. Burk RBL, Bollinger L, Johnson JC, Wada J, Radoshitzky SR. 7.  et al. 2016. Neglected filoviruses. FEMS Microbiol. Rev. 40:1–26 [Google Scholar]
  8. Feldman HSA, Geisbert TW. 8.  2013. Filoviridae: Marburg and Ebola viruses. Fields Virology DM Knipe, PM Howley 923–56 Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 6th ed.. [Google Scholar]
  9. Kuhn J, Becker S, Ebihara H, Geisbert TW, Jahrling PB. 9.  et al. 2011. Family Filoviridae In Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses, ed. AMQ King, MJ Adams, EB Carstens, et al., pp. 655–71 London: Elsevier [Google Scholar]
  10. Negredo A, Palacios G, Vazquez-Moron S, Gonzalez F, Dopazo H. 10.  et al. 2011. Discovery of an ebolavirus-like filovirus in Europe. PLOS Pathog 7:e1002304 [Google Scholar]
  11. Hoenen T, Feldmann H. 11.  2014. Reverse genetics systems as tools for the development of novel therapies against filoviruses. Expert Rev. Anti Infect. Ther. 12:1253–63 [Google Scholar]
  12. Banadyga L, Dolan MA, Ebihara H. 12.  2016. Rodent-adapted filoviruses and the molecular basis of pathogenesis. J. Mol. Biol. 428:3449–66 [Google Scholar]
  13. Mühlberger E. 13.  2007. Filovirus replication and transcription. Future Virol 2205–15 [Google Scholar]
  14. Basler CF. 14.  2015. Innate immune evasion by filoviruses. Virology 479–80:122–30 [Google Scholar]
  15. Messaoudi I, Amarasinghe GK, Basler CF. 15.  2015. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13:663–76 [Google Scholar]
  16. Basler CF. 16.  2013. A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein. Expert Rev. Anti Infect. Ther. 11:475–78 [Google Scholar]
  17. Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ. 17.  et al. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369–72 [Google Scholar]
  18. Groseth A, Feldmann H, Strong JE. 18.  2007. The ecology of Ebola virus. Trends Microbiol 15:408–16 [Google Scholar]
  19. Lam TT, Zhu H, Chong YL, Holmes EC, Guan Y. 19.  2015. Puzzling origins of the Ebola outbreak in the Democratic Republic of the Congo, 2014. J. Virol. 89:10130–32 [Google Scholar]
  20. Georges-Courbot MC, Sanchez A, Lu CY, Baize S, Leroy E. 20.  et al. 1997. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg. Infect. Dis. 3:59–62 [Google Scholar]
  21. Hoenen T, Safronetz D, Groseth A, Wollenberg KR, Koita OA. 21.  et al. 2015. Virology. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 348:117–19 [Google Scholar]
  22. Viana M, Mancy R, Biek R, Cleaveland S, Cross PC. 22.  et al. 2014. Assembling evidence for identifying reservoirs of infection. Trends Ecol. Evol. 29:270–79 [Google Scholar]
  23. Plowright RK, Eby P, Hudson PJ, Smith IL, Westcott D. 23.  et al. 2015. Ecological dynamics of emerging bat virus spillover. Proc. Biol. Sci. 282:20142124 [Google Scholar]
  24. Strong JE, Wong G, Jones SE, Grolla A, Theriault S. 24.  et al. 2008. Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway. PNAS 105:17982–87 [Google Scholar]
  25. Leendertz SAJ, Gogarten JF, Düx A, Calvignac-Spencer S, Leendertz FH. 25.  2015. Assessing the evidence supporting fruit bats as the primary reservoirs for Ebola viruses. Ecohealth 13:18–25 [Google Scholar]
  26. Pourrut X, Delicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy EM. 26.  2007. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J. Infect. Dis. 196:Suppl. 2S176–83 [Google Scholar]
  27. Jones MEB, Schuh AJ, Amman BR, Sealy TK, Zaki SR. 27.  et al. 2015. Experimental inoculation of Egyptian rousette bats (Rousettus aegyptiacus) with viruses of the Ebolavirus and Marburgvirus genera. Viruses 7:3420–42 [Google Scholar]
  28. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP. 28.  et al. 2009. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 9:723–28 [Google Scholar]
  29. Olival KJ, Hayman DT. 29.  2014. Filoviruses in bats: current knowledge and future directions. Viruses 6:1759–88 [Google Scholar]
  30. Wahl-Jensen VRS, de Kok-Mercado F. 30.  2014. Role of rodents and bats in human viral hemorrhagic fevers. Viral Hemorrhagic Fevers SKRD Singh 99–127 Boca Raton, FL: CRC Press [Google Scholar]
  31. Pigott DM, Golding N, Mylne A, Huang Z, Henry AJ. 31.  et al. 2014. Mapping the zoonotic niche of Ebola virus disease in Africa. eLife 3e04395
  32. 32. Cent. Dis. Control Prev. 2016. Outbreaks chronology: Ebola virus disease. April 14. http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html
  33. Glynn JR. 33.  2015. Age-specific incidence of Ebola virus disease. Lancet 386:432 [Google Scholar]
  34. Dean NE, Halloran ME, Yang Y, Longini IM. 34.  2016. Transmissibility and pathogenicity of Ebola virus: a systematic review and meta-analysis of household secondary attack rate and asymptomatic infection. Clin. Infect. Dis. 62:1277–86 [Google Scholar]
  35. Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P. 35.  et al. 1999. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Épidémies à Kikwit. J. Infect. Dis. 179:Suppl. 1S76–86 [Google Scholar]
  36. Fischer R, Judson S, Miazgowicz K, Bushmaker T, Prescott J, Munster VJ. 36.  2015. Ebola virus stability on surfaces and in fluids in simulated outbreak environments. Emerg. Infect. Dis. 21:1243–46 [Google Scholar]
  37. Ajelli M, Parlamento S, Bome D, Kebbi A, Atzori A. 37.  et al. 2015. The 2014 Ebola virus disease outbreak in Pujehun, Sierra Leone: epidemiology and impact of interventions. BMC Med 13:281 [Google Scholar]
  38. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. 38.  1999. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Épidémies à Kikwit. J. Infect. Dis. 179:Suppl. 1S87–91 [Google Scholar]
  39. Bower H, Johnson S, Bangura MS, Kamara AJ, Kamara O. 39.  et al. 2016. Exposure-specific and age-specific attack rates for Ebola virus disease in Ebola-affected households, Sierra Leone. Emerg. Infect. Dis. 22:1403–11 [Google Scholar]
  40. Nielsen CF, Kidd S, Sillah AR, Davis E, Mermin J, Kilmarx PH. 40.  2015. Improving burial practices and cemetery management during an Ebola virus disease epidemic—Sierra Leone, 2014. Morb. Mortal. Wkly. Rep. 64:20–27 [Google Scholar]
  41. Lokuge K, Caleo G, Greig J, Duncombe J, McWilliam N. 41.  et al. 2016. Successful control of Ebola virus disease: analysis of service based data from rural Sierra Leone. PLOS Negl. Trop. Dis. 10:e0004498 [Google Scholar]
  42. Johnson E, Jaax N, White J, Jahrling P. 42.  1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76:227–36 [Google Scholar]
  43. Zumbrun EE, Bloomfield HA, Dye JM, Hunter TC, Dabisch PA. 43.  et al. 2012. A characterization of aerosolized Sudan virus infection in African green monkeys, cynomolgus macaques, and rhesus macaques. Viruses 4:2115–36 [Google Scholar]
  44. Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D. 44.  et al. 2011. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J. Infect. Dis. 204:200–8 [Google Scholar]
  45. Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK. 45.  2011. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect 13:930–36 [Google Scholar]
  46. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. 46.  2012. Transmission of Ebola virus from pigs to non-human primates. Sci. Rep. 2:811 [Google Scholar]
  47. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS. 47.  et al. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163:2347–70 [Google Scholar]
  48. Edwards JK, Kleine C, Munster V, Giuliani R, Massaquoi M. 48.  et al. 2015. Interpretation of negative molecular test results in patients with suspected or confirmed Ebola virus disease: report of two cases. Open Forum Infect. Dis. 2:ofv137 [Google Scholar]
  49. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A. 49.  et al. 2015. Blood kinetics of Ebola virus in survivors and nonsurvivors. J. Clin. Invest. 125:4692–98 [Google Scholar]
  50. Davis KJ, Anderson AO, Geisbert TW, Steele KE, Geisbert JB. 50.  et al. 1997. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch. Pathol. Lab. Med. 121:805–19 [Google Scholar]
  51. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. 51.  2015. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J. Pathol. 235:153–74 [Google Scholar]
  52. Yen B, Mulder LC, Martinez O, Basler CF. 52.  2014. Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J. Virol. 88:12500–10 [Google Scholar]
  53. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J. 53.  et al. 2000. The Ebola virus VP35 protein functions as a type I IFN antagonist. PNAS 97:12289–94 [Google Scholar]
  54. Leung DW, Prins KC, Basler CF, Amarasinghe GK. 54.  2010. Ebolavirus VP35 is a multifunctional virulence factor. Virulence 1:526–31 [Google Scholar]
  55. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML. 55.  et al. 2006. Ebola virus VP24 binds karyopherin α1 and blocks STAT1 nuclear accumulation. J. Virol. 80:5156–67 [Google Scholar]
  56. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A. 56.  et al. 2014. Ebola virus VP24 targets a unique NLS-binding site on karyopherin5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 16:187–200 [Google Scholar]
  57. Zhang AP, Abelson DM, Bornholdt ZA, Liu T, Woods VL Jr., Saphire EO. 57.  2012. The ebolavirus VP24 interferon antagonist: Know your enemy. Virulence 3:440–45 [Google Scholar]
  58. Ansari AA. 58.  2014. Clinical features and pathobiology of Ebolavirus infection. J. Autoimmun. 55:1–9 [Google Scholar]
  59. Zhang AP, Bornholdt ZA, Liu T, Abelson DM, Lee DE. 59.  et al. 2012. The Ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLOS Pathog 8:e1002550 [Google Scholar]
  60. Cardenas WB, Loo YM, Gale M Jr., Hartman AL, Kimberlin CR. 60.  et al. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80:5168–78 [Google Scholar]
  61. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E. 61.  et al. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77:7945–56 [Google Scholar]
  62. Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF. 62.  et al. 2009. Structure of the Ebola VP35 interferon inhibitory domain. PNAS 106:411–16 [Google Scholar]
  63. Leung LW, Park MS, Martinez O, Valmas C, Lopez CB, Basler CF. 63.  2011. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol. Cell Biol. 89:792–802 [Google Scholar]
  64. Jin H, Yan Z, Prabhakar BS, Feng Z, Ma Y. 64.  et al. 2010. The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J. Gen. Virol. 91:352–61 [Google Scholar]
  65. Ito H, Watanabe S, Takada A, Kawaoka Y. 65.  2001. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75:1576–80 [Google Scholar]
  66. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P. 66.  2010. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLOS Pathog 6:e1001098 [Google Scholar]
  67. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ. 67.  et al. 2004. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol. 78:10370–77 [Google Scholar]
  68. Zaki SR, Goldsmith CS. 68.  1999. Pathologic features of filovirus infections in humans. Curr. Top. Microbiol. Immunol. 235:97–116 [Google Scholar]
  69. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. 69.  2003. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188:1618–29 [Google Scholar]
  70. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. 70.  2010. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLOS Negl. Trop. Dis. 4:e837 [Google Scholar]
  71. Gupta M, Spiropoulou C, Rollin PE. 71.  2007. Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology 364:45–54 [Google Scholar]
  72. Bradfute SB, Swanson PE, Smith MA, Watanabe E, McDunn JE. 72.  et al. 2010. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J. Immunol. 184:327–35 [Google Scholar]
  73. Hensley LE, Young HA, Jahrling PB, Geisbert TW. 73.  2002. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80:169–79 [Google Scholar]
  74. Rasmussen AL. 74.  2016. Host factors in Ebola infection. Annu. Rev. Genom. Hum. Genet. 17:333–51 [Google Scholar]
  75. 75. WHO (World Health Organ.) Int. Study Team. 1978. Ebola haemorrhagic fever in Sudan, 1976. Bull. World Health Organ 56:247–70 [Google Scholar]
  76. Zaki SR, Shieh WJ, Greer PW, Goldsmith CS, Ferebee T. 76.  et al. 1999. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit. J. Infect. Dis. 179:Suppl. 1S36–47 [Google Scholar]
  77. Sureau PH. 77.  1989. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev. Infect. Dis. 11:Suppl. 4S790–93 [Google Scholar]
  78. Dietrich M, Schumacher HH, Peters D, Knobloch J. 78.  1978. Human pathology of Ebola (Maridi) virus infection in the Sudan. Ebola Virus Haemorrhagic Fever SR Pattyn 37–41 Amsterdam: Elsevier [Google Scholar]
  79. Murphy FA. 79.  1978. Pathology of Ebola virus infection. Ebola Virus Haemorrhagic Fever SR Pattyn 43–59 Amsterdam: Elsevier [Google Scholar]
  80. Ellis DS, Simpson IH, Francis DP, Knobloch J, Bowen ET. 80.  et al. 1978. Ultrastructure of Ebola virus particles in human liver. J. Clin. Pathol. 31:201–8 [Google Scholar]
  81. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A. 81.  et al. 1999. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis. 179:Suppl. 1S1–7 [Google Scholar]
  82. Rollin PE, Bausch DG, Sanchez A. 82.  2007. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J. Infect. Dis. 196:Suppl. 2S364–71 [Google Scholar]
  83. Twenhafel NA, Mattix ME, Johnson JC, Robinson CG, Pratt WD. 83.  et al. 2013. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Vet. Pathol. 50:514–29 [Google Scholar]
  84. Cournac JM, Karkowski L, Bordes J, Aletti M, Duron S. 84.  et al. 2016. Rhabdomyolysis in Ebola virus disease. Results of an observational study in a treatment center in Guinea. Clin. Infect. Dis. 62:19–23 [Google Scholar]
  85. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM. 85.  et al. 2015. Persistence of Ebola virus in ocular fluid during convalescence. N. Engl. J. Med. 372:2423–27 [Google Scholar]
  86. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D. 86.  et al. 1999. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J. Infect. Dis. 179:Suppl. 1S13–14 [Google Scholar]
  87. Deen GF, Knust B, Broutet N, Sesay FR, Formenty P. 87.  et al. 2015. Ebola RNA persistence in semen of Ebola virus disease survivors—preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1511410
  88. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A. 88.  et al. 1999. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179:Suppl. 1S170–76 [Google Scholar]
  89. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y. 89.  2000. Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278:20–26 [Google Scholar]
  90. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. 90.  2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6:886–89 [Google Scholar]
  91. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J. 91.  et al. 1999. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J. Infect. Dis. 179:Suppl. 1S188–91 [Google Scholar]
  92. Edwards KM, Davis JE, Browne KA, Sutton VR, Trapani JA. 92.  1999. Anti-viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule-bound pathways of apoptosis induction. Immunol. Cell Biol. 77:76–89 [Google Scholar]
  93. Topham NJ, Hewitt EW. 93.  2009. Natural killer cell cytotoxicity: How do they pull the trigger?. Immunology 128:7–15 [Google Scholar]
  94. Palmer RM, Bridge L, Foxwell NA, Moncada S. 94.  1992. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br. J. Pharmacol. 105:11–12 [Google Scholar]
  95. Wei T, Chen C, Hou J, Xin W, Mori A. 95.  2000. Nitric oxide induces oxidative stress and apoptosis in neuronal cells. Biochim. Biophys. Acta 1498:72–79 [Google Scholar]
  96. Neumann FJ, Ott I, Marx N, Luther T, Kenngott S. 96.  et al. 1997. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler. Thromb. Vasc. Biol. 17:3399–405 [Google Scholar]
  97. Nemerson Y. 97.  1988. Tissue factor and hemostasis. Blood 71:1–8 [Google Scholar]
  98. Conway EM, Rosenberg RD. 98.  1988. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol. Cell Biol. 8:5588–92 [Google Scholar]
  99. Mammen EF. 99.  1992. Coagulation abnormalities in liver disease. Hematol. Oncol. Clin. North Am. 6:1247–57 [Google Scholar]
  100. Taylor FB Jr., Toh CH, Hoots WK, Wada H, Levi M. 100.  2001. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86:1327–30 [Google Scholar]
  101. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. 101.  1996. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70:2208–14 [Google Scholar]
  102. Jerca L, Jerca O, Mancas G, Constantinescu I, Lupusoru R. 102.  2002. Mechanism of action and biochemical effects of nitric oxide (NO). J. Prev. Med. 10:35–45 [Google Scholar]
  103. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. 103.  1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651–61 [Google Scholar]
  104. Bray M. 104.  2001. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82:1365–73 [Google Scholar]
  105. Ebihara H, Takada A, Kobasa D, Jones S, Neumann G. 105.  et al. 2006. Molecular determinants of Ebola virus virulence in mice. PLOS Pathog 2:e73 [Google Scholar]
  106. Bray M, Hatfill S, Hensley L, Huggins JW. 106.  2001. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol. 125:243–53 [Google Scholar]
  107. Rasmussen AL, Okumura A, Ferris MT, Green R, Feldmann F. 107.  et al. 2014. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 346:987–91 [Google Scholar]
  108. Volchkov VE, Chepurnov AA, Volchkova VA, Ternovoj VA, Klenk HD. 108.  2000. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277:147–55 [Google Scholar]
  109. Cross RW, Fenton KA, Geisbert JB, Mire CE, Geisbert TW. 109.  2015. Modeling the disease course of Zaire ebolavirus infection in the outbred guinea pig. J. Infect. Dis. 212:Suppl. 2S305–15 [Google Scholar]
  110. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM. 110.  et al. 1999. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179:Suppl. 1S203–17 [Google Scholar]
  111. Ryabchikova E, Kolesnikova L, Smolina M, Tkachev V, Pereboeva L. 111.  et al. 1996. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch. Virol. 141:909–21 [Google Scholar]
  112. Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R. 112.  et al. 2013. A Syrian golden hamster model recapitulating Ebola hemorrhagic fever. J. Infect. Dis. 207:306–18 [Google Scholar]
  113. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. 113.  1978. The pathology of experimental Ebola virus infection in monkeys. J. Pathol. 125:131–38 [Google Scholar]
  114. Ryabchikova EI, Kolesnikova LV, Luchko SV. 114.  1999. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179:Suppl. 1S199–202 [Google Scholar]
  115. Carrion R Jr., Ro Y, Hoosien K, Ticer A, Brasky K. 115.  et al. 2011. A small nonhuman primate model for filovirus-induced disease. Virology 420:117–24 [Google Scholar]
  116. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP. 116.  et al. 1996. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch. Pathol. Lab. Med. 120:140–55 [Google Scholar]
  117. Alves DA, Honko AN, Kortepeter MG, Sun M, Johnson JC. 117.  et al. 2016. Necrotizing scleritis, conjunctivitis, and other pathologic findings in the left eye and brain of an Ebola virus-infected rhesus macaque (Macaca mulatta) with apparent recovery and a delayed time of death. J. Infect. Dis. 213:57–60 [Google Scholar]
  118. Heffernan RT, Pambo B, Hatchett RJ, Leman PA, Swanepoel R, Ryder RW. 118.  2005. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooue-Ivindo region, Northeastern Gabon, 1997. J. Infect. Dis. 191:964–68 [Google Scholar]
  119. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC. 119.  et al. 2000. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355:2210–15 [Google Scholar]
  120. Akerlund E, Prescott J, Tampellini L. 120.  2015. Shedding of Ebola virus in an asymptomatic pregnant woman. N. Engl. J. Med. 372:2467–69 [Google Scholar]
  121. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK. 121.  et al. 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N. Engl. J. Med. 371:2092–100 [Google Scholar]
  122. Faye O, Andronico A, Faye O, Salje H, Boelle PY. 122.  et al. 2015. Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study. PLOS Med 12:e1001908 [Google Scholar]
  123. de La Vega MA, Caleo G, Audet J, Qiu X, Kozak RA. 123.  et al. 2015. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J. Clin. Invest. 125:4421–28 [Google Scholar]
  124. Li J, Duan HJ, Chen HY, Ji YJ, Zhang X. 124.  et al. 2016. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int. J. Infect. Dis. 42:34–39 [Google Scholar]
  125. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. 125.  2014. Ebola virus disease in West Africa—clinical manifestations and management. N. Engl. J. Med. 371:2054–57 [Google Scholar]
  126. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L. 126.  et al. 2014. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371:2402–9 [Google Scholar]
  127. Chertow DS, Uyeki TM, DuPont HL. 127.  2015. Loperamide therapy for voluminous diarrhea in Ebola virus disease. J. Infect. Dis. 211:1036–37 [Google Scholar]
  128. Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V. 128.  et al. 2015. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect. Dis. 15:1292–99 [Google Scholar]
  129. Uyeki TM, Mehta AK, Davey RT Jr., Liddell AM, Wolf T. 129.  et al. 2016. Clinical management of Ebola virus disease in the United States and Europe. N. Engl. J. Med. 374:636–46 [Google Scholar]
  130. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK. 130.  et al. 2015. Human Ebola virus infection results in substantial immune activation. PNAS 112:4719–24 [Google Scholar]
  131. Wolf T, Kann G, Becker S, Stephan C, Brodt HR. 131.  et al. 2015. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385:1428–35 [Google Scholar]
  132. Russo T, Costa C, Crujo C, Lopes AI. 132.  2012. Protein-losing gastropathy associated with cytomegalovirus infection in a child. BMJ Case Rep 2012:bcr0120125679 [Google Scholar]
  133. Megged O, Schlesinger Y. 133.  2008. Cytomegalovirus-associated protein-losing gastropathy in childhood. Eur. J. Pediatr. 167:1217–20 [Google Scholar]
  134. Zivin JR, Gooley T, Zager RA, Ryan MJ. 134.  2001. Hypocalcemia: a pervasive metabolic abnormality in the critically ill. Am. J. Kidney Dis. 37:689–98 [Google Scholar]
  135. Chertow DS, Nath A, Suffredini AF, Danner RL, Reich DS. 135.  et al. 2016. Severe meningoencephalitis in a case of Ebola virus disease: a case report. Ann. Intern. Med. 165:301–4 [Google Scholar]
  136. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G. 136.  et al. 2014. A case of severe Ebola virus infection complicated by gram-negative septicemia. N. Engl. J. Med. 371:2394–401 [Google Scholar]
  137. Liddell AM, Davey RT Jr., Mehta AK, Varkey JB, Kraft CS. 137.  et al. 2015. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann. Intern. Med. 163:81–90 [Google Scholar]
  138. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ. 138.  et al. 1999. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J. Infect. Dis. 179:Suppl. 1S28–35 [Google Scholar]
  139. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML. 139.  et al. 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179:Suppl. 1S177–87 [Google Scholar]
  140. Howlett P, Brown C, Helderman T, Brooks T, Lisk D. 140.  et al. 2016. Ebola virus disease complicated by late-onset encephalitis and polyarthritis, Sierra Leone. Emerg. Infect. Dis. 22:150–52 [Google Scholar]
  141. Bechtelsheimer H, Korb G, Gedigk P. 141.  1970. The “Marburg-virus”-hepatitis. Studies in man and guinea pigs. Virchows Arch. A Pathol. Anat. Histol. 351:273–90 [Google Scholar]
  142. Slenczka WG. 142.  1999. The Marburg virus outbreak of 1967 and subsequent episodes. Curr. Top. Microbiol. Immunol. 235:49–75 [Google Scholar]
  143. Larsen T, Stevens EL, Davis KJ, Geisbert JB, Daddario-DiCaprio KM. 143.  et al. 2007. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J. Infect. Dis. 196:Suppl. 2S323–28 [Google Scholar]
  144. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ. 144.  et al. 2015. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 61:496–502 [Google Scholar]
  145. Connor MJ Jr., Kraft C, Mehta AK, Varkey JB, Lyon GM. 145.  et al. 2015. Successful delivery of RRT in Ebola virus disease. J. Am. Soc. Nephrol. 26:31–37 [Google Scholar]
  146. Kortepeter MG, Bausch DG, Bray M. 146.  2011. Basic clinical and laboratory features of filoviral hemorrhagic fever. J. Infect. Dis. 204:Suppl. 3S810–16 [Google Scholar]
  147. Chertow DSCR, Arai AE, Davey RT. 147.  2016. Cardiac MRI findings suggest myocarditis in severe Ebola virus disease. JACC Cardiovasc. Imaging. http://dx.doi.org/10.1016/j.jcmg.2016.06.004. In press
  148. Lazzerini PE, Capecchi PL, Laghi-Pasini F. 148.  2015. Long QT syndrome: an emerging role for inflammation and immunity. Front. Cardiovasc. Med. 2:26 [Google Scholar]
  149. de Wit E, Falzarano D, Onyango C, Rosenke K, Marzi A. 149.  et al. 2016. The merits of malaria diagnostics during an Ebola virus disease outbreak. Emerg. Infect. Dis. 22:323–26 [Google Scholar]
  150. Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De Roo A. 150.  et al. 1999. Ebola hemorrhagic fever and pregnancy. J. Infect. Dis. 179:Suppl. 1S11–12 [Google Scholar]
  151. Caluwaerts S, Fautsch T, Lagrou D, Moreau M, Modet Camara A. 151.  et al. 2016. Dilemmas in managing pregnant women with Ebola: 2 case reports. Clin. Infect. Dis. 62:903–5 [Google Scholar]
  152. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I. 152.  et al. 2016. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388:498–503 [Google Scholar]
  153. Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K. 153.  et al. 2016. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect. Dis. 16:331–38 [Google Scholar]
  154. Tiffany A, Vetter P, Mattia J, Dayer JA, Bartsch M. 154.  et al. 2016. Ebola virus disease complications as experienced by survivors in Sierra Leone. Clin. Infect. Dis. 62:1360–66 [Google Scholar]
  155. Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR. 155.  et al. 2015. Molecular evidence of sexual transmission of Ebola virus. N. Engl. J. Med. 373:2448–54 [Google Scholar]
  156. Prescott J, Bushmaker T, Fischer R, Miazgowicz K, Judson S, Munster VJ. 156.  2015. Postmortem stability of Ebola virus. Emerg. Infect. Dis. 21:856–59 [Google Scholar]
  157. Nordenstedt H, Bah EI, de la Vega MA, Barry M, N'Faly M. 157.  et al. 2016. Ebola virus in breast milk in an Ebola virus-positive mother with twin babies, Guinea, 2015. Emerg. Infect. Dis. 22:759–60 [Google Scholar]
  158. Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G, de la Calle F, Borobia AM. 158.  et al. 2015. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir. Med. 3:554–62 [Google Scholar]
  159. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M. 159.  et al. 2007. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J. Infect. Dis. 196:Suppl. 2S142–47 [Google Scholar]
  160. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 160.  2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 100:446–54 [Google Scholar]
  161. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. 161.  2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105:17–21 [Google Scholar]
  162. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. 162.  2014. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 104:153–55 [Google Scholar]
  163. Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH. 163.  et al. 2016. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLOS Med 13:e1001967 [Google Scholar]
  164. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A. 164.  et al. 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179:Suppl. 1S18–23 [Google Scholar]
  165. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P. 165.  et al. 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374:33–42 [Google Scholar]
  166. Qiu X, Wong G, Audet J, Bello A, Fernando L. 166.  et al. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53 [Google Scholar]
  167. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB. 167.  et al. 2006. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193:1650–57 [Google Scholar]
  168. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN. 168.  et al. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375:1896–905 [Google Scholar]
  169. Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV. 169.  et al. 2012. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4:2806–30 [Google Scholar]
  170. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL. 170.  et al. 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402–5 [Google Scholar]
  171. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL. 171.  et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381–85 [Google Scholar]
  172. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB. 172.  et al. 2003. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362:1953–58 [Google Scholar]
  173. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL. 173.  et al. 2007. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 196:Suppl. 2S390–99 [Google Scholar]
  174. Shuaib F, Gunnala R, Musa EO, Mahoney FJ, Oguntimehin O. 174.  et al. 2014. Ebola virus disease outbreak—Nigeria, July–September 2014. Morb. Mortal. Wkly. Rep. 63:867–72 [Google Scholar]
  175. Martins KA, Jahrling PB, Bavari S, Kuhn JH. 175.  2016. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev. Vaccines 15:1101–12 [Google Scholar]
  176. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ. 176.  et al. 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857–66 [Google Scholar]
  177. Routh J. 177.  2015. Study of Ebola survivors opens in Liberia: research to examine long-term health effects of Ebola virus disease NIAID News Release, June 17. https://www.niaid.nih.gov/news-events/study-ebola-survivors-opens-liberia
  178. 178. Cent. Dis. Control Prev. 2016. Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) Q&A. April 20. http://www.cdc.gov/vhf/ebola/strive/qa.html
  179. Leligdowicz A, Fischer WA, Uyeki TM. 179.  2016. Ebola virus disease and critical illness. Crit. Care 20:217 https://doi.org/10.1186/s13054-016-1352-2 [Google Scholar]
/content/journals/10.1146/annurev-pathol-052016-100506
Loading
/content/journals/10.1146/annurev-pathol-052016-100506
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error